What initial laboratory tests should be ordered for a patient presenting with blood in the stool?

Initial Laboratory Tests for Blood in Stool

For a patient presenting with blood in the stool, order a complete blood count (CBC) with hemoglobin and hematocrit, serum electrolytes, blood urea nitrogen (BUN), creatinine, coagulation studies (PT/INR, aPTT), and assess vital signs to determine hemodynamic stability and bleeding severity. 1

Immediate Assessment and Risk Stratification

Hemodynamic Evaluation

• Check vital signs immediately to calculate the shock index (heart rate ÷ systolic blood pressure)—if >1, the patient requires ICU admission and urgent intervention rather than routine workup 2
• Assess for signs of hemodynamic instability including tachycardia, hypotension, or orthostatic changes that indicate significant blood loss 1

Essential Laboratory Panel

• Complete blood count (CBC) to determine hemoglobin and hematocrit levels, which guide transfusion decisions and assess severity of anemia 1, 2
• Serum electrolytes to identify metabolic derangements from bleeding 1
• Blood urea nitrogen (BUN) and creatinine to assess renal function and identify upper GI bleeding (elevated BUN:creatinine ratio suggests upper GI source) 1
• Coagulation studies (PT/INR, aPTT) to evaluate bleeding risk and guide reversal strategies if needed 1
• Blood type and crossmatch should be ordered immediately for patients with signs of severe bleeding to prepare for potential transfusion 1, 2

Additional Screening Tests Based on Clinical Context

For Suspected Inflammatory Bowel Disease

• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to assess inflammatory activity, though these lack specificity to differentiate UC from infectious causes 1
• Serum albumin as hypoalbuminemia correlates with disease severity in acute severe colitis 1
• Iron studies (serum iron, ferritin, total iron-binding capacity) to evaluate for iron deficiency anemia from chronic blood loss 1
• Vitamin D level as deficiency is common in IBD patients 1

For Suspected Infectious Etiology

• Stool culture for common bacterial pathogens (Salmonella, Shigella, Campylobacter, E. coli O157:H7) 1
• Clostridium difficile toxin assay is mandatory in all patients with colitis relapse or new-onset bloody diarrhea 1
• Stool examination for ova and parasites if travel history, endemic area exposure, or persistent diarrhea suggests parasitic infection 1

For Screening and Risk Assessment

• Fecal occult blood testing (FOBT) or fecal immunochemical test (FIT) has limited utility in acute bleeding but may be useful in chronic occult bleeding scenarios 1
• Note that iron preparations cause false-positive guaiac-based tests in 50-65% of cases, so document any iron supplementation 3
• Fecal calprotectin can help distinguish inflammatory from non-inflammatory causes of bleeding, though it lacks specificity for the type of inflammation 1

Critical Clinical Pitfalls

Avoid These Common Errors

• Never delay resuscitation for diagnostic testing in hemodynamically unstable patients—this increases mortality 2
• Do not assume hemorrhoids are the sole cause of a positive FIT (≥25 μg/g hemoglobin)—complete colonic evaluation with colonoscopy is mandatory to exclude colorectal cancer 4
• Do not rely on negative FOBT to exclude significant pathology in iron deficiency anemia, as guaiac and immunochemical tests are insensitive for proximal gut bleeding 5
• Recognize that 15% of lower GI bleeding originates from upper GI sources, so maintain broad differential 2

Special Populations Requiring Additional Testing

• Pregnancy test (with consent) in women of childbearing age presenting with rectal bleeding 1
• Liver function tests and coagulation panel in patients with known or suspected portal hypertension and anorectal varices 1
• Consider bone marrow sampling in anemic patients without iron deficiency evidence, as alternative causes (chronic kidney disease, hematologic disorders) are more likely than GI bleeding 6

Transfusion Thresholds Based on Laboratory Results

• Maintain hemoglobin >7 g/dL in hemodynamically stable patients 2
• Target hemoglobin >9 g/dL in patients with massive bleeding, significant cardiovascular comorbidities, or ongoing hemodynamic instability 2
• Correct coagulopathy with fresh frozen plasma or specific factor replacement if INR >1.5 or aPTT >1.5 times normal in actively bleeding patients 1